Background and Purpose-Cerebral small vessel disease (SVD) is the most common cause of vascular dementia. Interest in the use of surrogate markers is increasing. The aims of this study were to determine if brain volume was different between patients with SVD and control subjects, whether it correlated with cognition in SVD, and whether changes in brain volume could be detected during prospective follow-up. Methods-Thirty-five patients (mean age, 68.8 years) who had a lacunar stroke and radiological evidence of confluent leukoaraiosis and 70 age-and gender-matched control subjects were recruited. Whole-brain T1-weighted imaging and neuropsychological testing were performed after 1 year on all patients and after 2 years for the control subjects. Fully automated software was used to determine brain volume and percentage brain volume change. An executive function score was derived. Results-There was a significant difference in brain volume between the patients with SVD and control subjects (meanϮSD [mL] 1529Ϯ84 versus 1573Ϯ69, Pϭ0.019). In the patients with SVD, there was a significant association between brain volume and executive function (rϭ0.501, PϽ0.05). The meanϮSD yearly brain atrophy rate for patients with SVD and control subjects was significantly different (Ϫ0.914%Ϯ0.8% versus Ϫ0.498%Ϯ0. 4%, respectively, Pϭ0.017). No change in executive function score was detected over this period. Key Words: brain atrophy Ⅲ cerebral small vessel disease Ⅲ cognitive impairment Ⅲ longitudinal study Ⅲ MRI Ⅲ surrogate marker C erebral small vessel disease (SVD) is a major cause of stroke, age-related cognitive decline, and vascular dementia. 1 Despite its importance, few studies have specifically investigated treatment in this stroke subtype. 2,3 This is due to a number of issues that complicate assessment of treatment efficacy: the risk of recurrent stroke is relatively low with an annual rate of 0.25%, 4 the rate of progression to dementia is slow, 4 and repeated cognitive testing is associated with a learning effect that reduces sensitivity to longitudinal decline. Therefore, large sample sizes are required to determine treatment efficacy when using stroke and dementia as end points. This has led to the suggestion that imaging may provide useful surrogate markers for SVD to assess therapeutic approaches at an early stage. 5 A number of criteria have been proposed for the definition of an effective surrogate marker for treatment trials. 6 The first criterion is that the marker must be able to predict the natural course of the disease, that is, it should correlate with relevant clinical features, for example, cognitive function, in both crosssectional and longitudinal studies.
C erebral small vessel disease (SVD) is a major cause of stroke, age-related cognitive decline, and vascular dementia. 1 Despite its importance, few studies have specifically investigated treatment in this stroke subtype. 2, 3 This is due to a number of issues that complicate assessment of treatment efficacy: the risk of recurrent stroke is relatively low with an annual rate of 0.25%, 4 the rate of progression to dementia is slow, 4 and repeated cognitive testing is associated with a learning effect that reduces sensitivity to longitudinal decline. Therefore, large sample sizes are required to determine treatment efficacy when using stroke and dementia as end points. This has led to the suggestion that imaging may provide useful surrogate markers for SVD to assess therapeutic approaches at an early stage. 5 A number of criteria have been proposed for the definition of an effective surrogate marker for treatment trials. 6 The first criterion is that the marker must be able to predict the natural course of the disease, that is, it should correlate with relevant clinical features, for example, cognitive function, in both crosssectional and longitudinal studies.
In multiple sclerosis, imaging parameters have been demonstrated to have high sensitivity for detection of disease activity, which is better than clinical scores. 7 Brain atrophy has been used as an outcome measure in treatment trials. 8, 9 In comparison to multiple sclerosis, there are less data on brain atrophy in SVD with white matter hyperintensity lesion volume being the most widely reported. The progression of lesion volume in SVD has been demonstrated over follow-up periods as short as 2 years. 10 However, correlations between lesion volume and clinical parameters, in particular cognition, have been weak or nonsignificant in a number (but not all) of cross-sectional [11] [12] [13] and longitudinal 14, 15 studies. A further limitation to using lesion load as a surrogate marker is that its measurement is time-consuming and has significant measurement error, 16 although automatic reliable measures are becoming available. 17 An alternative, promising surrogate marker that may be computed from conventional MR sequences is brain volume. Brain volume has been shown to correlate with cognition and disability scales. 12, 13, 16, 18, 19 However, there are limited data on the rate of atrophy in SVD. An annual rate of 0.5% was found in younger patients with the genetic form of SVD, cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 19 compared with a rate of 0.38% in normal middle-aged and elderly individuals. 20 A small group of patients with vascular dementia demonstrated a greatly increased rate compared with normal older adults (1.9% annually). 21 Currently, there are no data on the rate of atrophy on patients presenting with lacunar stroke rather than with dementia. It is important to study these individuals because they represent a group in whom treatment, before the onset of dementia, could prevent progression to dementia. In particular, these patients demonstrate significant but subtle cognitive impairments, particularly in executive function.
The aim of this study was to determine whether brain volume is decreased in patients with SVD with respect to normal ageing subjects, whether this decrease was correlated with cognition and disability, and whether changes in brain volume could be detected over a short time period of 1 year.
Methods

Subjects
Patients With SVD
Thirty-five patients presenting with a clinical lacunar stroke syndrome and with a corresponding lacunar infarct on MRI, in combination with confluent radiological leukoaraiosis, were recruited. Patients with other causes of stroke apart from SVD were excluded: cardioembolic source, large cerebral artery stenosis Ͼ50%, large (1.5 cm) subcortical infarcts, or any cortical infarcts. To exclude the effects of acute ischemia on cognition and MRI parameters at baseline, patients were imaged at least 3 months after their last stroke.
Normal Individuals
Seventy stroke-free normal older adults were recruited as part of the GENIE (St George's Neuropsychology and Imaging in the Elderly) study 22 and were included as the control group. The GENIE subjects were recruited by random sampling from a community population through family doctor lists. Any control subjects with a history of central nervous system disease or major psychiatric disease were excluded. Of the 663 contacted individuals, 408 responded, of whom 158 agreed to participate. Fifty-two were excluded leaving 106 individuals enrolled in the study.
Subject Assessment
Vascular risk factor assessment (blood pressure, diabetes, smoking status, and body mass index) was performed for all subjects as described previously. 16 Modified Rankin score was recorded as a measure of disability. 23 
Follow-Up
All the patients with SVD were invited to return for repeat imaging and neuropsychological assessment 1 year after the baseline appointment and 27 returned for scanning. For these patients, clinical data such as stroke/transient ischemic attack during the interim periods, vascular risk factors, and modified Rankin score were reassessed. As part of the GENIE study, individuals were invited to return for repeat imaging after 2 years and 56 did.
The local research ethics committee approved the study and all the subjects gave informed, written consent.
MRI Acquisition and Analysis
For all participants, longitudinal MRI was performed on a 1.5-T GE Signa MRI system (General Electric, Milwaukee, Wis) with a maximum gradient strength of 22 mTm Ϫ1 . A T1-weighted volume images (spoiled gradient recalled acquisition in steady state; 92 axial slices of 1.5-mm thickness, TR/TEϭ17/3 seconds, acquisition matrix 256ϫ256ϫ92, field of view 240ϫ240 mm, flip angle 10°) and fluid-attenuated inversion recovery images (TR/TEϭ9000/120s, inversion recovery time 2200 ms, 28 slices of 5-mm thickness) were acquired. The same imaging sequence was performed at each time point.
Images were transferred to a Sun workstation (Sun Microsystems, Mountain View, Calif) for further analysis. All analyses were performed blinded to the participant's identity. Brain volume was calculated at baseline using a fully automatic program SIENAX (Structural Image Evaluation, using Normalization, of AtrophyCross-sectional; www.fmrib.ox.ac.uk/fsl). 24 This first delineates the brain and skull from T1-weighted images and then normalizes the brain and skull to standard space. Brain volume is reported both as a raw value and relative to normalized skull size to reduce any head size-related variability between subjects.
For each subject, brain volume change was calculated longitudinally from the spoiled gradient recalled acquisition in steady state images using the fully automated image analysis program SIENA (Structural Image Evaluation, using Normalization, of Atrophy; www.fmrib.ox.ac.uk/fsl). 25 SIENA estimates the exterior surface of the skull and then coregisters the skull image data so that scans obtained at different time points are overlain in the same image space. It computes the brain and nonbrain edges at each time point and calculates the subsequent change in volume presented as a percentage change in brain volume between the scans.
Reproducibility tests on normal volunteers have been performed in previous studies and report an error of 0.15% for brain volume on repeated measures and 0.5% to 1% brain volume accuracy for a single time point (cross-sectional). 24 In the current study, to determine reproducibility within our sample, 2 scans were performed on the same day for 4 SVD subjects and 6 control subjects. SIENAX was then used to determine the immediate reproducibility in this cohort of subjects. The meanϮSD percentage brain volume difference between scans was 0.34%Ϯ0.5% for the patients with SVD and 0.06%Ϯ0.2% for control subjects.
A semiautomated program using the contour function of the Dispunc software was used to draw automatically around all the lesions on fluid-attenuated inversion recovery images (Christopher Plummer, University College London, London, UK). White matter hyperintensity lesion was defined as white matter areas with increased signal intensity on fluid-attenuated inversion recovery. White matter hyperintensity lesion load was calculated by dividing the white matter hyperintensity lesion volume by the nonnormalized brain volume and then expressed as a percentage. This was performed on 10 random patients with SVD by 2 raters (A.N. and S.L.). The interrater reliability as determined using Pearson correlation coefficient was rϭ0.996 (Pϭ0).
Neuropsychological Assessment
At baseline and follow-up, all subjects completed a range of neuropsychological tests within 1 month of MRI. The tests were chosen to assess a range of cognitive domains, especially executive function. The battery of tests administered is listed in Supplemental Table I (available at http://stroke.ahajournals.org). Assessment duration was approximately 30 to 45 minutes.
Statistical Analysis
Cross-Sectional
Differences in demographic characteristics between patients with SVD and control subjects were investigated using Student t tests for continuous data and 2 tests for discrete data. Group differences in brain volume were assessed using Student t tests. To determine if there were differences in brain volume between groups irrespective of vascular risk factors and lesion load, a multivariate analysis was performed with these variables as covariates. The following risk factors were used: age, gender, hypertension, smoking, diabetes, and body mass index.
To determine the relationship between baseline brain volume and lesion load, correlation coefficients were obtained (repeated to determine if the relationship was independent of vascular risk factors).
For the SVD cohort, to reduce the number of statistical comparisons, 1 composite neuropsychological scores (general cognition and executive function) were determined using principal components analysis as described previously. 16 The pattern of correlation between brain volume and these 2 scores, a memory score (the logical memory immediate recall score), and current IQ were calculated. These analyses were corrected for age, gender, and premorbid IQ using partial correlations.
Longitudinal
The baseline demographic and MR characteristics of the patients who dropped out were compared with patients who attended at both time points to establish whether the characteristics of the dropouts differed from those who attended.
Annual percentage brain volume change for the control subjects was calculated by dividing the percentage brain volume change between baseline and follow-up after 2 years by 2. The atrophy rate for the 2 groups was then compared using Student t tests (repeated to determine if the relationship was independent of vascular risk factors and lesion load).
The results of the individual neuropsychological tests were compared using paired tests. Where significant changes in cognitive abilities are observed, cognitive change was correlated with atrophy rate.
In the SVD and control cohorts, to identify factors that would predict the possible significant brain atrophy in both groups, multivariate analysis was run with percentage change in brain volume as the dependent variable and the following independent baseline variables: vascular risk factors, lesion load, and normalized brain volume. These factors were also compared in patients with SVD with fast decline (the upper quartile) compared with the remainder of the group to determine if there were any differences.
Results
Cross-Sectional Study
There were no differences between the groups for age, gender, or smoking status (Table) . In patients with SVD, hypertension and diabetes were more common and body mass index higher.
Mean brain volume was smaller in patients with SVD compared with control subjects (meanϮSD [mL] 1580Ϯ75 versus 1529Ϯ84, Pϭ0.003). This difference remained significant after controlling for vascular risk factors (Pϭ0.026), but not after additionally controlling for lesion load (Pϭ0.130).
MeanϮSD lesion load (%) was greater in patients with SVD compared with control subjects: 3.78Ϯ2.52 versus 0.55Ϯ0.72 (Pϭ0). There was a correlation between brain volume and lesion load (rϭϪ0.352, Pϭ0.0003; Figure 1 ), which persisted after controlling for vascular risk factors (rϭϪ0.250, Pϭ0.014).
In the SVD cohort, there was a correlation between brain volume and the composite global neuropsychology score (rϭ0.507, Pϭ0.032) and the composite executive function score (rϭ0.501, Pϭ0.034). The relationship between brain volume and cognition was independent of lesion load (global neuropsychology rϭ0. 493 
Longitudinal Study
There were no significant differences in either the baseline demographic characteristics or brain volume between the patients with SVD that attended at both time points and those who dropped out. No patients or control subjects had a stroke during follow-up.
MeanϮSE yearly brain atrophy rate was greater in SVD cases compared with control subjects (0.914%Ϯ0.16% versus 0.498%Ϯ0.05%, Pϭ0.017; Figure 2 ). This is significantly greater than the reported 0.15% brain volume change error. 24 After controlling for vascular risk factors, the significance of this difference reduced to 0.051. It was no longer significant after controlling for baseline lesion load (Pϭ0.280). In contrast, for the patients with SVD, over the period of 1 year, there was no significant change in any of the cognitive scores or the modified Rankin score. In view of the lack of change in cognition or the Rankin score, no correlation between these parameters and change in brain volume could be performed.
The results of the multivariate analysis contained only age as a factor predicting brain atrophy in the SVD cohort and this explained 18% of the variance of yearly brain volume change (Pϭ0.032; Supplemental Table II) . A similar multivariate analysis on the control subjects found that gender was the only factor predicting atrophy and explained 10% of the variance (Pϭ0.019). Comparing the upper quartile of patients with increased brain atrophy with the remainder of patients found that the patients with higher age and lower baseline brain volume had a greater atrophy rate (meanϮSD age 75.5Ϯ6.5 years versus 66.3Ϯ8.3 years, Pϭ0.016 and 
Discussion
In the analysis of baseline imaging, we demonstrated that brain volume is decreased in patients with SVD compared with age-matched control subjects and confirmed previous studies showing that in SVD brain volume correlates with cognitive scores. In our longitudinal follow-up we demonstrated that the rate of atrophy in patients with SVD, presenting with lacunar stroke and leukoaraiosis, is approximately 1% per annum and twice that found in age-matched control subjects. In contrast, no change in cognition could be detected over this time period. The sensitivity of brain volume measurements to change over time suggests it may be useful as a surrogate marker to monitor disease progress and assess the effect of therapeutic interventions. The atrophy rate of the control subjects of this study was 0.498%; this is consistent with the results of a community study on 329 aging subjects (annual atrophy rate of 0.38%). 20 The meanϮSD atrophy rate of the 25 patients with SVD in this study was 0.914%Ϯ0.8%, which is almost double the rate reported on 76 patients with CADASIL (0.56%Ϯ0.74%) 19 and half the rate reported on 9 patients with vascular dementia (1.9%Ϯ1.1%). 21 The lower rate in CADASIL cohorts is likely to be explained, at least partly, by the younger age of the CADASIL subjects. An additional factor may be the higher rate of hypertension rate in the SVD group (100% versus 24% in the CADASIL group). Hypertension is known to result in brain atrophy. 26 The higher rate in patients with vascular dementia may be due to this group being selected for their cognitive impairment and therefore having more severe vascular disease, although the small sample size makes reliable comparisons difficult.
The mechanism of brain atrophy in SVD is not fully understood. The pathological and physiological variables that can affect brain volume have been reviewed in the context of multiple sclerosis. 27 Axonal loss, resolution of inflammation and edema, gliosis (through retraction scarring), demyelination, dehydration, normal aging, and anti-inflammatory agents can result in a decrease in brain volume. No direct pathological studies have been performed looking at the histology underlying the changes in brain volume in SVD. It is possible that it is a direct result of microvascular disease. Alternatively, it may occur secondary to other processes such as white matter tract disruption with secondary atrophy. The reduction in the association between SVD and atrophy when white matter hyperintensity lesion load is controlled for would support the second explanation playing a role.
The lack of change in cognitive scores over the time period of 1 year could be explained by a number of factors. First, it is known that the rate of cognitive decline is slow and hence follow-up may be insufficient. Second, it may reflect a lack of sensitivity of the neuropsychology battery or learning effects of repeated assessments. Third, the sample size may be too small to detect a significant change. In view of this lack of change, a correlation analysis between change in cognitive scores and brain atrophy could not be performed. No significant correlation was found between baseline brain volume or change and modified Rankin score. This may be due to the nonparametric nature of this disability score or that the patients with SVD were minimally disabled with a mean Rankin score of 1.46.
Previous studies correlating brain volume with cognition have measured volume in specific brain compartments, namely the hippocampal and cortical gray matter volume 12, 18 or parenchymal brain volume. 13 Although this allows correlations with specific brain regions, it is more time-consuming and has higher measurement error. Measuring whole brain volume using a fully automated program is fast with low measurement error, which is advantageous when monitoring disease progression or as a surrogate marker. However, evaluation of specific brain region analysis could be interesting and a possibility in future studies.
Brain atrophy fulfills the first criterion for being a surrogate marker; it correlates with relevant clinical features in cross-sectional studies and it changes with time. The next step in establishing brain atrophy as a marker of disease progression is to assess the effect of treatment on the rate of atrophy. [16] 。使用 改良的 Rankin 评分来评估残疾程度 DASIL 患者脑萎缩率 (0.56%±0.74%) [19] 的 2 倍，是 报道的 9 位血管性痴呆患者脑萎缩率 (1.9%±1.1%) [21] 的一半。CADASIL 患者脑萎缩率更低，部分因为 
